The Phase 3 FLAURA2 trial (NCT04035486) continues to strengthen the role of combination therapy in the first-line management of EGFR-mutated (EGFRm) advanced non–small cell lung cancer (NSCLC). At ESMO 2025, investigators…
FLAURA2 Trial: Osimertinib Plus Chemotherapy Improves Overall Survival Across Prognostic Subgroups in EGFR-Mutated Advanced NSCLC — Presented at ESMO 2025
